Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma.
- Author:
Yang-feng DU
1
;
Rong-cheng LUO
;
Gui-ping LI
;
Ai-min LI
;
Xue-mei DING
;
Xiao YAN
;
Kai HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antibodies, Antinuclear; immunology; Antibodies, Monoclonal; therapeutic use; Carcinoma, Hepatocellular; pathology; radiotherapy; Cell Line, Tumor; Hepatitis B Surface Antigens; immunology; Humans; Immunoconjugates; therapeutic use; Immunoglobulin Fab Fragments; immunology; Iodine Radioisotopes; therapeutic use; Liver Neoplasms, Experimental; pathology; radiotherapy; Mice; Mice, Nude; Radioimmunotherapy; methods; Treatment Outcome; Xenograft Model Antitumor Assays
- From: Journal of Southern Medical University 2008;28(3):460-462
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the feasibility and efficacy of radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab (131 I-anti-HBsAg Fab) combined with 131 I-labeled anti-nucleus antigen monoclonal antibody chTNT (131 I-chTNT) in nude mice bearing human hepatocellular carcinoma.
METHODSNude mice bearing subcutaneous human hepatocellular carcinoma xenografts were treated by intratumoral injection of 131 I-anti-HBsAg Fab and/or 131 I-chTNT, and the changes in the tumor size and alterations in the radioactivity concentration in the tumor and non-tumor tissues were observed.
RESULTSThe tumor inhibition rate in mice treated with 131 I-anti-HBsAg Fab combined with 131 I-chTNT (73.09%) was significantly higher than that in mice treated with 131 I-anti-HBsAg Fab (47.8%) or 131 I-chTNT (54.26%) alone. Combined treatment also resulted in significantly higher tumor-to-normal radioactivity concentration ratios than the treatment with the single agents.
CONCLUSIONIntratumoral injection with 131 I-labeled monoclonal antibodies can increase the radioactivity concentration in the tumor and enhance the efficacy of the radioimmunotherapy in nude mice bearing human hepatocellular carcinoma.
